Adrabetadex for Patients With Nerve Symptoms of Niemann-Pick Type C Disease (NPC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03643562|
Recruitment Status : Recruiting
First Posted : August 23, 2018
Last Update Posted : July 7, 2020
This study was amended from extended access to a clinical trial. Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks.
Participants who were already taking adrabetadex will receive their stable dose. Participants who have not ever taken it will start by receiving 400 mg.
The study design will be like the expanded access by Rush University, but for children at least 4 years of age at screening.
Participants will receive treatment every 2 weeks until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason. Participants will not receive additional study treatment after their participation in this protocol.
|Condition or disease||Intervention/treatment||Phase|
|Niemann-Pick Type C Disease||Drug: Adrabetadex||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Continued treatment for children at least 4 years of age|
|Masking:||None (Open Label)|
|Official Title:||Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)|
|Actual Study Start Date :||June 18, 2018|
|Estimated Primary Completion Date :||May 22, 2021|
|Estimated Study Completion Date :||July 31, 2021|
Participants receive prescribed adrabetadex by intra-thecal injection
administered via lumbar puncture and intra-thecal infusion
- Clinician Global Impression of Change (Clinician-CGIC) [ Time Frame: within approximately 3 years ]The Clinician-CGIC is evaluated using a 7-point Likert scale ranging from 1 (marked improvement) from screening to 7 (marked worsening from screening) at the participant's last visit
- Composite Niemann Pick Type C Severity Scale (NPC-SS) [ Time Frame: within approximately 3 years ]Each of four NPC-SS components (ambulation, cognition, fine motor, and swallowing) are rated on a scale from 0 (better) to 5 (worse). The highest (worst) possible score is 20.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03643562
|Contact: Medical Information Call Center||800-556-3314 ext email@example.com|
|Study Director:||Global Clinical Leader||Mallinckrodt|